

### AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning on page 1, line 7 with the following text, which incorporate several amendments, as well as severing the original paragraph into three new paragraphs:

41 In the structure of the eye, the retina is present in the eyeground and controls the function of the eye to recognize the presence or absence and shape of an object by the presence of a visual cell layer of the retina. In recent years, patients with eye diseases undergo objective ~~test of~~ retinal function test by the determination of electroretinogram (hereinafter sometimes referred to merely as ERG) ~~and the~~. This determination is then utilized for the diagnosis of ~~the condition~~ retinal conditions.

       The ERG consists of an a-wave, a b-wave, a c-wave and the like, ~~and~~. The a-wave is primarily ~~considered to mainly reflect~~ reflects the function of visual cells, the b-wave is ~~considered to reflect~~ reflects the function of the bipolar cell layer (mainly Müller cells) and the c-wave is ~~considered to reflect~~ reflects the function of the retinal pigment epithelium. When the retinal function is damaged for some reason, it ~~appears as changes~~ manifests in a change in the peak latency and amplitude of each wave. For example, in the case of diabetic retinopathy, ~~it is known that~~ the peak latency of each wave is extended from the early stage and the amplitude is attenuated; in degenerative disease of retina, such as pigmentary retinal degeneration, all waves are attenuated and disappear ~~in degenerative disease of retina, such as pigmentary retinal degeneration~~; and each wave becomes attenuated depending on the stages of disease in retinochoroidal ~~disorder~~ disorders, such as central retinal artery occlusion, central retinal vein thrombosis, fundus hypertonicus, retinal detachment and the like.

       While the b-wave ~~and the like are originated~~ originates from the source located more toward the central side of the retina than the visual cell from which the a-wave is ~~originated~~ originates, when the light reaches the retina, the visual cell is first excited and the b-wave and

Cont  
A1  
the like are first generated when the excitement is transmitted to the retinal cells on the central side. Therefore, even when the source of origin is other than visual cell, the waves are under strong influence of the function of the visual cell. In other words, when the function of the visual cell is damaged, ERG components become abnormal even if the source of origin of the b-wave and the like is normal. Therefore, in ERG, the a-wave is the most important component, and if changes in peak latency and amplitude of a wave, which are caused by the damaged function of visual cell, can be suppressed or recovered, the visual cell function disorder is expected to be effectively treated.

Please replace the paragraph beginning on page 2, line 22 with the following text:

A2 R<sup>8</sup> and R<sup>9</sup> are each independently ~~show~~ a hydrogen atom or hydroxyl;

Please replace the paragraph beginning on page 3, line 6 with the following text:

A3 R<sup>11</sup> and R<sup>12</sup> are each independently ~~show~~ a hydrogen atom, alkyl, aryl or tosyl;

Please replace the paragraph beginning on page 3, line 7 with the following text:

A4 R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>22</sup> and R<sup>23</sup> are each independently ~~show~~ a hydrogen atom or alkyl;

Please replace the paragraph beginning on page 3, line 12 with the following text:

A5 In addition to the meaning noted above, Y, R<sup>10</sup> and R<sup>23</sup> may ~~show~~ be, together with the carbon atom they bind with, a saturated or unsaturated 5 or 6-membered heterocyclic group containing nitrogen atom, sulfur atom and/or oxygen atom, the heterocyclic group being optionally substituted by one or more group(s) selected from alkyl, hydroxy, alkyloxy, benzyl, a group of the formula -CH<sub>2</sub>Se(C<sub>6</sub>H<sub>5</sub>), and alkyl substituted by one or more hydroxy,

Please replace the paragraph beginning on page 3, line 31 with the following text:

A6 The IL-2 inhibitor to be used in the present invention is not particularly limited and may be any as long as it has an IL-2 inhibitory activity. One example thereof is an IL-2 production inhibitor. ~~Other~~ Another example is an IL-2 signal transduction inhibitor.

Contd  
A6  
Preferable examples thereof include macrolide compounds such as FK506, Ascomycin derivative, Rapamycin derivative and the like and cyclosporins and the like.

Please replace the paragraph beginning on page 4, line 4 with the following text:

A7  
Specific examples of the macrolide compound include a tricyclo compound (I) of the following formula and a pharmaceutically acceptable salt thereof.

Please replace the paragraph beginning on page 4, line 13 with the following text:

A8  
 $R^8$  and  $R^9$  are each independently show a hydrogen atom or hydroxyl;

Please replace the paragraph beginning on page 4, line 20 with the following text:

A9  
 $R^{11}$  and  $R^{12}$  are each independently show a hydrogen atom, alkyl, aryl or tosyl;

Please replace the paragraph beginning on page 4, line 21 with the following text:

A10  
 $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{22}$  and  $R^{23}$  are each independently show a hydrogen atom or alkyl;

Please replace the paragraph beginning on page 5, line 2 with the following text:

A11  
In addition to the meaning noted above, Y,  $R^{10}$  and  $R^{23}$  may show be, together with the carbon atom they bind with, a saturated or unsaturated 5 or 6-membered heterocyclic group containing nitrogen atom, sulfur atom and/or oxygen atom, the heterocyclic group being optionally substituted by one or more group(s) selected from alkyl, hydroxy, alkyloxy, benzyl, a group of the formula  $-\text{CH}_2\text{Se}(\text{C}_6\text{H}_5)$ , and alkyl substituted by one or more hydroxy,

Please replace the paragraph beginning on page 10, line 22 with the following text:

A12  
The pharmaceutically acceptable salt of the tricyclo compound (I), Rapamycin and derivatives thereof are nontoxic and pharmaceutically acceptable conventional salts, which are exemplified by salts with inorganic or organic base such as alkali metal salt (e.g., sodium salt, potassium salt and the like), alkaline earth metal salt (e.g., calcium salt, magnesium salt and the like), ammonium salt, and amine salt (e.g., triethylamine salt, N-benzyl-N-methylamine salt and the like).

Please replace the paragraph beginning on page 10, line 32 with the following text:

A13 The interleukin 2 inhibitor to be used in the present invention can be used as a pharmaceutical agent for human and animals, and can be administered systemically or locally by oral administration, intravenous administration (inclusive of transfusion), subcutaneous administration, rectal or ~~virginal~~ vaginal administration, administration to local site of the eye (inclusive of eye ointment). In consideration of systemic influence, significant expression of the effect and the like, it is particularly preferably used in the form for local administration to the eye.

Please replace the paragraph beginning on page 16, line 1 with the following text:

**CLAIMES CLAIMS**